SCHEMBL4745945

SCHEMBL4745945

Cc1ccc2c(c1)c(-c1cc3c4ccccc4ccc3c3ccccc13)cc1c3ccc(C)c4c3c(cc21)-c1ncccc1-4

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPRT1 P00492 3/20 0.37
ALDH1A1 P00352 3/20 0.36
MAPT P10636 3/20 0.36
CYP1A2 P05177 2/20 0.36
MAOA P21397 1/20 0.36
LCK P06239 1/20 0.36
FYN P06241 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ACHE P22303 1/20 0.36
SLC6A2 P23975 1/20 0.36
AHR P35869 1/20 0.36
TOP2A P11388 1/20 0.36
CYP2A6 P11509 1/20 0.35
CCR1 P32246 3/20 0.35
CCR8 P51685 3/20 0.35
CYP3A4 P08684 2/20 0.35
LMNA P02545 2/20 0.35
APEX1 P27695 1/20 0.35
MAPK1 P28482 1/20 0.35
PMP22 Q01453 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4745849 0.96 CCR1 (0.35) HPRT1ALDH1A1MAPTCYP1A2MAOA
SCHEMBL4745860 0.94 MAOA (0.35) ALDH1A1MAPTCYP1A2MAOAFYN
SCHEMBL4745959 0.94 CYP1A2 (0.35) HPRT1ALDH1A1MAPTCYP1A2MAOA
SCHEMBL4746409 0.92 PDK2 (0.33) ALDH1A1MAPTCYP1A2TOP2ACCR1
SCHEMBL4746180 0.91 TOP2A (0.37) ALDH1A1MAPTCYP1A2MAOATOP2A
SCHEMBL4746466 0.91 TOP2A (0.32) ALDH1A1MAPTCYP1A2TOP2ACCR1
SCHEMBL4746394 0.91 MEN1 (0.32) ALDH1A1MAPTCYP1A2TOP2ACCR1
SCHEMBL4746272 0.90 MAPT (0.32) MAPTTOP2ACCR1CCR8MAPK1
SCHEMBL4745985 0.90 BCHE (0.33) ALDH1A1TOP2ABCHE
SCHEMBL4746461 0.90 TOP2A (0.33) ALDH1A1MAPTTOP2ACCR1CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 HPRT1 152/4885ALDH1A1 179/4885MAPT 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.